Neoantigen Market Insight

Key Highlights

• As per a French study conducted by Mezquita et al. titled “Prognostic Value of HLA-A2 Status in Advanced Non-Small Cell Lung Cancer Patients,” out of 545 stage IIIB/IV NSCLC patients included 508 (93%) had stage IV, 407 (75%) had an adenocarcinoma and median age was 61 years. In addition, the overall rate of HLA-A2 positivity was 48%. 

Request for unlocking CAGR of Neoantigen-based Personalized Cancer Therapeutic Vaccines Market

DelveInsight’s “Neoantigen-based Personalized Cancer Therapeutic Vaccines – Competitive Landsscape and Market Forecast – 2032” report delivers an in-depth understanding of the Neoantigen-based Personalized Cancer Therapeutic Vaccines, historical and forecasted epidemiology as well as the Neoantigen-based Personalized Cancer Therapeutic Vaccines market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Neoantigen-based Personalized Cancer Therapeutic Vaccines market report provides current treatment practices, emerging vaccines, Neoantigen-based Personalized Cancer Therapeutic Vaccines market share of the individual therapies, and current and forecasted Neoantigen-based Personalized Cancer Therapeutic Vaccines market size from 2019 to 2032, segmented by seven major markets. The report also covers current Neoantigen-based Personalized Cancer Therapeutic Vaccines treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom 
• Japan

Study period: 2019–2032

Neoantigen-based Personalized Cancer Therapeutic Vaccines Market Disease: Understanding and Treatment Algorithm

The DelveInsight’s Neoantigen-based Personalized Cancer Therapeutic Vaccines market report gives a thorough understanding of Personalized Cancer Therapeutic Vaccines. Therapies by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Cancer therapeutic Vaccines use weakened or killed viruses, bacteria, or other germs to start an immune response in the body. These vaccines are designed to work in a similar manner, teaching the immune system to recognize, attack and destroy cancer cells. Neoantigen-based Personalized Cancer Therapeutic Vaccines allow the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells. Neoantigen-based Personalized Cancer Therapeutic Vaccines are one way to utilize the body’s immune system to fight cancer. Cancer neoantigens derived from random somatic mutations in tumor tissue represent a promising approach of targets for the cancer immunotherapies including cancer vaccine. Vaccination against the tumor-specific neoantigens minimizes the potential induction of central and peripheral tolerance as well as the risk of autoimmunity. Neoantigen-based cancer vaccines have recently shown marked therapeutic potential in both preclinical and early-phase as well as late-phase clinical studies. Neoantigens are highly immunogenic as they are not expressed in normal tissues. They can activate CD4+ and CD8+ T cells to generate immune response and have the potential to become new targets of tumor immunotherapy. The development of bioinformatics technology has accelerated the identification of neoantigens. The combination of different algorithms to identify and predict the affinity of neoantigens to major histocompatibility complexes (MHCs) or the immunogenicity of neoantigens is mainly based on the whole-exome sequencing technology. Tumor vaccines targeting neoantigens mainly include nucleic acid, dendritic cell (DC)-based, tumor cell, and synthetic long peptide (SLP) vaccines. There have been only two Cancer Therapeutic Vaccines approved till now: Bacillus Calmette-Guérin (BCG) and Provenge. BCG was approved by the FDA in 1990 as a vaccine for early-stage bladder cancer. It became the standard and most successful treatment of NMIBC following TUR is the intravesical instillation of BCG as an immunotherapeutic agent to reduce the risks of recurrence and progression into MIBC. However, accompanied by several drawbacks such as treatment failure (i.e. recurrence or progression) or emergence of resistance, which has been reported in more than 40% of cases, side effects that can be local or systemic, and the short residence of the instilled BCG in the Urothelial lumen due to frequent bladder emptying. Following BCG, the FDA approved Dendron’s Provenge (sipuleucel-T) as the first therapeutic cancer vaccine in men with prostate cancer; the company later went bankrupt due to several issues. Also it is important to note that till date no neo-antigen based personalized vaccine has been approved.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Drug Chapters

The vaccine chapter segment of the Neoantigen-based Personalized Cancer Therapeutic report encloses the detailed analysis of Neoantigen-based Personalized Cancer Therapeutics’ marketed Vaccines and late-stage (Phase III and Phase II) Neoantigen-based Personalized Cancer Therapeutic Vaccines pipeline. It also helps understand the Neoantigen-based Personalized Cancer Therapeutic Vaccines clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included Vaccines, and the latest news and press releases.

Emerging Neoantigen-based Personalized Cancer Therapeutic Vaccines Drugs

The report details the emerging Neoantigen-based Personalized Cancer Therapeutic Vaccines therapies under the late and mid-stage of development for Neoantigen-based Personalized Cancer Therapeutic Vaccines treatment.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Market Outlook

The Neoantigen-based Personalized Cancer Therapeutic Vaccines market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Neoantigen-based Personalized Cancer Therapeutic Vaccines market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the Neoantigen-based Personalized Cancer Therapeutic Vaccines market trend of each marketed vaccines and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Neoantigen-based Personalized Cancer Therapeutic Vaccines market in 7MM is expected to witness a major change in the study period 2019–2032.

Key findings

This section includes a glimpse of the Neoantigen-based Personalized Cancer Therapeutic Vaccines market in 7MM.

The United States: Neoantigen-based Personalized Cancer Therapeutic Vaccines market Outlook

This section provides the total Neoantigen-based Personalized Cancer Therapeutic Vaccines market size and market size by therapies in the United States.

EU4 and the United Kingdom Countries: Neoantigen-based Personalized Cancer Therapeutic Vaccines market Outlook

The total Neoantigen-based Personalized Cancer Therapeutic Vaccines market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan: Neoantigen-based Personalized Cancer Therapeutic Vaccines market Outlook

The total Neoantigen-based Personalized Cancer Therapeutic Vaccines market size and market size by therapies in Japan is also mentioned.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Neoantigen-based Personalized Cancer Therapeutic Vaccines market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Neoantigen-based Personalized Cancer Therapeutic Vaccines market uptake by vaccines, patient uptake by therapies, and sales of each vaccine.  

This will help in understanding the Neoantigen-based Personalized Cancer Therapeutic Vaccines with the most rapid uptake and the reasons behind the maximal use of new vaccines and allows the comparison of the vaccines based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses ‘Neoantigen-based Personalized Cancer Therapeutic Vaccines’ key players involved in developing targeted therapeutics.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Clinical Trial development activities

The Neoantigen-based Personalized Cancer Therapeutic Vaccines Clinical Trial report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Neoantigen-based Personalized Cancer Therapeutic Vaccines emerging therapies.

Learn more about emerging therapies and key companies: Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Insight

Neoantigen-based Personalized Cancer Therapeutic Vaccines Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Neoantigen-based Personalized Cancer Therapeutic Vaccines domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Neoantigen-based Personalized Cancer Therapeutic Vaccines market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Neoantigen-based Personalized Cancer Therapeutic Vaccines market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Neoantigen-based Personalized Cancer Therapeutic Vaccines Market Report

• Descriptive overview of Neoantigen-based Personalized Cancer Therapeutic Vaccines, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the Neoantigen-based Personalized Cancer Therapeutic Vaccines epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for Neoantigen-based Personalized Cancer Therapeutic Vaccines, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the Neoantigen-based Personalized Cancer Therapeutic Vaccines market; historical and forecasted covering drug outreach in the 7MM
• Detailed Patient-Based Market Forecasting determines the trends shaping and driving the global Neoantigen-based Personalized Cancer Therapeutic Vaccines market

Neoantigen-based Personalized Cancer Therapeutic Vaccines Market Report Highlights

• In the coming years, the Neoantigen-based Personalized Cancer Therapeutic Vaccines market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Neoantigen-based Personalized Cancer Therapeutic Vaccines R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition   
• Major players are involved in developing Neoantigen-based Personalized Cancer Therapeutic Vaccines therapies. The launch of emerging therapies will significantly impact the Neoantigen-based Personalized Cancer Therapeutic Vaccines market
• A better understanding of Neoantigen-based Personalized Cancer Therapeutic Vaccines pathogenesis will also contribute to the development of novel therapeutics for Neoantigen-based Personalized Cancer Therapeutic Vaccines 
• Our in-depth analysis of the Neoantigen-based Personalized Cancer Therapeutic Vaccines pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed Neoantigen-based Personalized Cancer Therapeutic Vaccines clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Neoantigen-based Personalized Cancer Therapeutic Vaccines Report Insights

• Patient-Based Market Forecasting 
• Therapeutic approaches
• Neoantigen-based Personalized Cancer Therapeutic Vaccines pipeline analysis
• Neoantigen-based Personalized Cancer Therapeutic Vaccines market size and trends
• Neoantigen-based Personalized Cancer Therapeutic Vaccines market opportunities
• Impact of upcoming therapies

Neoantigen-based Personalized Cancer Therapeutic Vaccines Report Key Strengths

• 11 years’ forecast
• 7MM coverage
• Key cross competition
• KOL views
• Neoantigen-based Personalized Cancer Therapeutic Vaccines uptake

Neoantigen-based Personalized Cancer Therapeutic Vaccines Report Assessment

• Current treatment practices
• Unmet needs
• Neoantigen-based Personalized Cancer Therapeutic Vaccines pipeline product profiles
• Neoantigen-based Personalized Cancer Therapeutic Vaccines market attractiveness

Key Questions

Neoantigen-based Personalized Cancer Therapeutic Vaccines market insights:

• What would be the Neoantigen-based Personalized Cancer Therapeutic Vaccines market growth till 2032, and what will be the resultant market size in 2032?
•  What was the Neoantigen-based Personalized Cancer Therapeutic Vaccines class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the Neoantigen-based Personalized Cancer Therapeutic Vaccines total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest Neoantigen-based Personalized Cancer Therapeutic Vaccines market size during the forecast period (2019–2032)
• How would the unmet needs affect the Neoantigen-based Personalized Cancer Therapeutic Vaccines market dynamics and subsequent analysis of the associated trends?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Neoantigen-based Personalized Cancer Therapeutic Vaccines in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Neoantigen-based Personalized Cancer Therapeutic Vaccines therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neoantigen-based Personalized Cancer Therapeutic Vaccines and its status, along with the challenges faced?

Reasons to Buy

• The Patient-Based Market Forecast analysis will help in developing business strategies by understanding trends shaping and driving the Neoantigen-based Personalized Cancer Therapeutic Vaccines market
• Organize sales and marketing efforts by identifying the best opportunities for Neoantigen-based Personalized Cancer Therapeutic Vaccines in the US, Europe (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors